Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597879 | 0.88 | P2RX7 (0.51) | ALDH1A1LMNATP53NAMPTMAPT | |
| SCHEMBL3602014 | 0.87 | NAMPT (0.42) | NAMPTGPR119USP30KMT2AMEN1 | |
| SCHEMBL3606960 | 0.85 | KMT2A (0.58) | ALDH1A1LMNATP53MAPTKMT2A | |
| SCHEMBL3605934 | 0.85 | NAMPT (0.48) | NAMPTMAPTGPR119USP30KMT2A | |
| SCHEMBL3607841 | 0.82 | NPC1 (0.46) | ALDH1A1NAMPTMAPTKMT2AMEN1 | |
| SCHEMBL3600238 | 0.81 | USP30 (0.49) | ALDH1A1LMNATP53MAPTGPR119 | |
| SCHEMBL3599783 | 0.79 | MEN1 (0.47) | ALDH1A1TP53NAMPTMAPTUSP30 | |
| SCHEMBL3592513 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPTGPR119USP30TSHR | |
| SCHEMBL3600776 | 0.78 | KEAP1 (0.49) | LMNANAMPTGPR119 | |
| SCHEMBL3601902 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTUSP30TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | TAAR1 71/4885ALDH1A1 1162/4885LMNA 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.